We can target, starve, penetrate, and destroy tumors. We have demonstrated checkpoint immunomodulation and have been able to show that co-expressing two different moieties on a single cell generates a synergistic response (Company Pipeline, Rubius Therapeutics, OCT 2, 2017, View Source [SID1234520728]). We are building a combinatorial portfolio of binding, stimulation, and killing modalities in a range of hematological and solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!